UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The utility of massively parallel sequencing for posterior polymorphous corneal dystrophy type 3 molecular diagnosis

Davidson, A; (2019) The utility of massively parallel sequencing for posterior polymorphous corneal dystrophy type 3 molecular diagnosis. Experimental Eye Research , 182 pp. 160-166. 10.1016/j.exer.2019.03.002. Green open access

[thumbnail of Article]
Preview
Text (Article)
Davidson_ZEB1_revision_FINAL.pdf - Accepted Version

Download (167kB) | Preview
[thumbnail of Figure 1]
Preview
Image (Figure 1)
Figure1_ZEB1.tif - Accepted Version

Download (11MB) | Preview
[thumbnail of Figure 2]
Preview
Image (Figure 2)
Figure2_ZEB1.tif - Accepted Version

Download (7MB) | Preview
[thumbnail of Figure 3]
Preview
Image (Figure 3)
Figure3_Zeb1.tif - Accepted Version

Download (4MB) | Preview
[thumbnail of Figure 4]
Preview
Image (Figure 4)
Figure4_ZEB1.tif - Accepted Version

Download (10MB) | Preview
[thumbnail of Supplementary Material]
Preview
Text (Supplementary Material)
Davidson_Supplementary Material ZEB1 paper_LD.pdf - Accepted Version

Download (2MB) | Preview

Abstract

The aim of this study was to identify the molecular genetic cause of disease in posterior polymorphous corneal dystrophy (PPCD) probands of diverse origin and to assess the utility of massively parallel sequencing in the detection of ZEB1 mutations. We investigated a total of 12 families (five British, four Czech, one Slovak and two Swiss). Ten novel and two recurrent disease-causing mutations in ZEB1, were identified in probands by Sanger (n=5), exome (n=4) and genome (n=3) sequencing. Sanger sequencing was used to confirm the mutations detected by massively parallel sequencing, and to perform segregation analysis. Genome sequencing revealed that one proband harboured a novel ~0.34 Mb heterozygous de novo deletion spanning exons 1-7 and part of exon 8. Transcript analysis confirmed that the ZEB1 transcript is detectable in blood-derived RNA samples and that the disease-associated variant c.482-2A>G leads to aberrant pre-mRNA splicing. De novo mutations, which are a feature of PPCD3, were found in the current study with an incidence rate of at least 16.6%. In general, massively parallel sequencing is a time-efficient way to detect PPCD3-associated mutations and, importantly, genome sequencing enables the identification of full or partial heterozygous ZEB1 deletions that can evade detection by both Sanger and exome sequencing. These findings contribute to our understanding of PPCD3, for which currently, 49 pathogenic variants have been identified, all of which are predicted to be null alleles.

Type: Article
Title: The utility of massively parallel sequencing for posterior polymorphous corneal dystrophy type 3 molecular diagnosis
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.exer.2019.03.002
Publisher version: https://doi.org/10.1016/j.exer.2019.03.002
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: ZEB1; posterior polymorphous corneal dystrophy type 3; massively parallel sequencing; exome; genome; aberrant splicing; breakpoint mapping
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
URI: https://discovery.ucl.ac.uk/id/eprint/10069706
Downloads since deposit
41Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item